The HER-2 negative breast cancer therapeutics commonly used include chemotherapy drugs like paclitaxel, docetaxel, and targeted therapy drugs like CDK 4/6 inhibitors. Meanwhile, diagnostic products include kits, reagents, and instruments used for identifying the presence of hormone receptors like estrogen receptor (ER) and progesterone receptor (PR) in breast tumor cells to decide the course of treatment.

The Global HER-2 Negative Breast Cancer Market is estimated to be valued at US$ 15982.51 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 To 2031.

Key Takeaways
Key players operating in the HER-2 negative breast cancer are Robert Bosch GmbH (Germany), HELLA KGaA (Germany), Continental AG (Germany), Denso Corporation (Japan), Delphi Automotive PLC (U.K.), Autoliv Inc. (Sweden), and Valeo S.A. (France) are the system manufacturers and companies such as Infineon Technologies AG (Germany). Some of the key opportunities in the HER-2 negative breast cancer market are increasing investments by key players for the development of targeted therapies, growing awareness about early detection and improved diagnosis using advanced screening tests, and rising number of clinical trials evaluating novel combination therapies. Geographically, North America is expected to dominate the global market due to the increasing incidence of breast cancer and growing awareness. However, Asia Pacific is anticipated to exhibit the highest growth during the forecast period with growing healthcare expenditure and increasing focus of international players.

Market Drivers
The increasing number of ongoing clinical trials for the development of newer therapeutic options like immunotherapy, PARP inhibitors is anticipated to drive the HER-2 Negative Breast Cancer Cases Market Size . According to clinicaltrials.gov, as of June 2022, there were over 1200 active clinical studies evaluating different targeted therapies, immunotherapies, and combination regimens for HER-2 negative breast cancer treatment.

Market Restrains
However, the high cost of targeted therapies, lack of awareness about advanced treatment options in low and middle-income countries, and heterogeneity of HER-2 negative breast cancer limiting the scope of personalized treatment can hamper the market growth.

Segment Analysis
The HER-2 negative breast cancer market can be segmented as ductal carcinoma in situ (DCIS) and Invasive ductal carcinoma (IDC) sub segments. The IDC segment is dominating the market as it accounts for around 80% of all breast cancer cases. In IDC cancer spreads to other parts of the breast from the milk ducts to other tissues of the breast. The aggressive nature and higher prevalence of IDC cases makes this the dominating sub segment in the HER-2 negative breast cancer market.

Global Analysis
North America holds the largest share in the overall HER-2 negative breast cancer market during the forecast period. This is attributed to the high prevalence of breast cancer cases and rising awareness regarding treatment options in the region. Asia Pacific is expected to grow at the highest CAGR driven by the rapidly increasing patient population, improving healthcare infrastructure, and rising medical tourism in the region. Key players are expanding their presence in emerging markets of Asia Pacific to tap the growth opportunities in the region.

Get more insights on This Topic- HER-2 Negative Breast Cancer Market